It remains unclear if the human coronary vasculature is inherently sensitive to changes in arterial 2 PO2 and PCO2 or if coronary vascular responses are the result of concomitant increases in 3 myocardial O2 consumption/demand (MVO2). We hypothesized that the coronary vascular 4 response to PO2 and PCO2 would be attenuated in healthy men when MVO2 was attenuated with 5 1-adrenergic receptor blockade. Healthy men (n=11; age: 25 ± 1 years) received intravenous 6 esmolol (1-adrenergic receptor antagonist) or volume-matched saline in a double-blind, 7 randomized, crossover study, and were exposed to poikilocapnic hypoxia, isocapnic hypoxia, 8 and hypercapnic hypoxia. Measurements made at baseline and following 5-min of steady state at 9 each gas manipulation included left anterior descending coronary blood velocity (LADV; 10 Doppler echocardiography), heart rate and arterial blood pressure. LADV values at the end of 11 each hypoxic condition were compared between esmolol and placebo. In humans, arterial hypoxemia led to an increase in epicardial coronary artery blood velocity. β1-23 adrenergic receptor blockade did not diminish the hypoxemic coronary response despite reduced 24 myocardial O2 demand. These data indicate hypoxemia can regulate coronary blood flow 25 independent of myocardial O2 consumption. A plateau in the LADVmean-RPP relationship 26 suggested a β1-adrenergic receptor mediated, feed-forward epicardial coronary artery dilation. In 27 addition, we observed a synergistic effect of PO2 and PCO2 during hypercapnic hypoxia. 28
New & Noteworthy 22
In humans, arterial hypoxemia led to an increase in epicardial coronary artery blood velocity. β1-23 adrenergic receptor blockade did not diminish the hypoxemic coronary response despite reduced 24 myocardial O2 demand. These data indicate hypoxemia can regulate coronary blood flow 25 independent of myocardial O2 consumption. A plateau in the LADVmean-RPP relationship 26 suggested a β1-adrenergic receptor mediated, feed-forward epicardial coronary artery dilation. In 27 addition, we observed a synergistic effect of PO2 and PCO2 during hypercapnic hypoxia. 28
Introduction 32
The limited anaerobic capacity of the myocardium and near maximal O2 extraction from the 33 coronary circulation at rest requires a close match of myocardial O2 demand and coronary blood 34 flow (14). Myocardial O2 consumption/demand is closely related to myocardial contractile force 35 and heart rate. Physiological increases in myocardial O2 demand require coronary vasodilation 36 to increase coronary blood flow thereby maintaining O2 delivery and cardiac function. 37
Mechanisms responsible for matching coronary blood flow to myocardial O2 demand have been 38 extensively reviewed and include vascular smooth muscle responses, endothelial release of 39 vasoactive substances, adrenergic stimulation and metabolic feedback control to changes in 40 arterial O2 and CO2 tensions (41). However, in healthy humans, separating the direct vascular 41 effects of vasoactive stimuli from the indirect effects on myocardial O2 demand is challenging 42 due to the redundant and highly integrated mechanisms involved. 43
Exposure to acute systemic hypoxia or hypercapnia leads to increased sympathetic nerve 44 activity (SNA) and associated catecholamine release from sympathetic nerve terminals and 45 adrenal medulla (47). Increased catecholamines stimulate β-adrenergic receptors within the 46 myocardium leading to positive chronotropic and inotropic responses that elevate heart rate (HR) 47 attenuated when myocardial O2 demand was reduced. In contrast to our hypothesis, the coronary 77 vasodilator response to hypoxemia was conserved during blockade of β1-adrenergic receptors. 78
Methods 79

Ethical Approval 80
The protocol for this study was approved by the Clinical Research Ethics Board at the University 81 of British Columbia and conformed to Canada's Tri-Council Policy Statement for the ethical 82 conduct for research involving humans as well as the Declaration of Helsinki. All participants 83 provided written, informed consent prior to experimentation. 84
85
Participants 86
Eleven healthy males with no history of cardiovascular or pulmonary disease participated in this 87 study. Participants completed a questionnaire to screen for previous cardiovascular or 88 pulmonary disease and to ensure they met inclusion criteria. Participants were excluded if they 89 were hypertensive (systolic blood pressure > 140 mmHg; diastolic blood pressure > 90 mmHg), 90 obese (BMI > 30 kg/m 2 ), or if the blood velocity from the left anterior descending coronary 91 artery could not be sufficiently measured by transthoracic Doppler ultrasound. Pulmonary 92 function was assessed by spirometry according to recommended guidelines (28) and included 93 measurement of the forced expiratory volume in 1s (FEV1) to forced vital capacity (FVC) ratio 94 (FEV1/FVC). Participants who did not achieve a FEV1/FVC ratio >75% of predicted were 95 excluded from the experiment. Participants refrained from exercise, alcohol and caffeine for 24 96 hours prior to experimentation. All participants provided written, informed consent prior to 97 experimentation. All experiments were conducted in Kelowna, BC, Canada at an elevation of 98 344m. 99
Experimental Protocol 102
In a double blind, placebo controlled, randomized crossover design, participants received an 
Echocardiographic measurements 152
All echocardiographic images were collected by two experienced sonographers using a 153 commercially available ultrasound machine (Vivid E9, GE) with a M5S 5 MHz ultrasound probe 154 or a 3V 3D-array ultrasound transducer, and saved for offline analysis with commercially 155 available software (EchoPAC v.13, GE). The epicardial portion of the left anterior descending 156 (LAD) coronary artery near the left ventricular apex was visualized as previously described to 157 obtain mean LAD blood velocity (LADVmean) and maximum LAD blood velocity (LADVmax and EF measurements were used to calculate an estimate of the left ventricular end-systolic 165 elastance (Ees) and used as an index of myocardial contractility as previously described (6, 10). 166
All echocardiographic measurements are reported as an average of 3 cardiac cycles. 167
Two indices of myocardial O2 demand were calculated. First, the minute mechanical energy of 170 the left-ventricle (MELV) was estimated from the derived area bound by the Ees and a simplified 171 pressure-volume loop as previously described (6). Briefly, the total energy (PVA) was taken as 172 the sum of stroke work and the elastic potential energy. The PVA in mmHg was converted to 173 joules (J) using a factor of 1.3 x 10 -4 and multiplied by HR to give the MELV reported in J/min as 174 previously described (6, 10). The second index of myocardial O2 demand RPP, was calculated 175 as the product of HR and beat-by-beat systolic blood pressure (SBP). The measurement of RPP 176 has been shown to correlate well with direct myocardial O2 demand measurements (22) . 177
Statistical Analysis 179
Our primary outcome variable is the difference in LADVmean between placebo and esmolol in 180 each hypoxic condition. Our sample size was estimated based on previously published data from 181 our laboratory (6) such that a difference in LADVmean of 2 cm/s between placebo and esmolol 182 could be resolved with a pooled standard deviation of 1.9 cm/s and a power >0.85. A two-by-183 four repeated measures analysis of variance was used to compare cardiovascular, respiratory and 184 echocardiographic measurements between drug condition (i.e. placebo or esmolol) and each end-185 tidal gas manipulation (i.e. baseline, poikilocapnic, isocapnic, and hypercapnic hypoxia). When 186 significant F-ratios were present, a Tukey's HSD post-hoc test was applied to determine where 187 statistical differences lay. Additionally, a mixed effect linear model was constructed using 188
LADVmean as the dependent variable, drug as a categorical predictor, and PETO2, PETCO2, and 189 1A and B provide 15-sec group mean (n=11) PETCO2 and PETO2 values during end-tidal gas 210 manipulation with and without β1-adrenergic receptor blockade. The hypoxic stimulus was 211 similar between placebo and β1-adrenergic receptor blockade with PETO2 and SpO2 both being 212 reduced from baseline and not different between poikilocapnic, isocapnic or hypercapnic 213 hypoxia. PETCO2 was also similar between placebo and β1-adrenergic receptor blockade, and 214 was reduced from baseline during poikilocapnic hypoxia, consistent with baseline during 215 Table 2 outlines select cardiovascular measurements during baseline and each end-tidal gas 219 manipulation with placebo and β1-adrenergic receptor blockade. All end-tidal gas manipulations 220 caused an increase in SBP from baseline during placebo, however, with β1-adrenergic receptor 221 blockade only hypercapnic hypoxia increased SBP. A significant interaction effect for SBP was 222 identified; post-hoc analysis determined SBP was attenuated by β1-adrenergic receptor blockade 223 during poikilocapnic (P = 0.04) and hypercapnic hypoxia (P < 0.01) but not isocapnic hypoxia (P 224 = 0.06). Diastolic blood pressure (DBP) and MAP were not influenced by poikilocapnic and 225 isocapnic hypoxia but increased from baseline with hypercapnic hypoxia. Both DBP and MAP 226
were unaffected by β1-adrenergic receptor blockade. Heart rate increased from baseline in 227 response to all end-tidal gas manipulations (P < 0.01) and tended to be reduced by β1-adrenergic 228 receptor blockade (P = 0.09). Left ventricular EDV was similar between drug conditions (P = 229 0.9) while ESV tended to be greater with β1-adrenergic receptor blockade (P = 0.09). Isocapnic 230 hypoxia reduced both EDV and ESV (P < 0.05), while hypercapnic hypoxia only reduced ESV 231 (P < 0.01). During placebo, Ees increased from baseline during all end-tidal gas manipulations 232 and was attenuated by β1-adrenergic receptor blockade. 233
234
Coronary vascular response 235
The LADVmean and LADVmax responses to end-tidal gas manipulations with placebo infusion and 236 β1-adrenergic receptor blockade are outlined in figure 2A and B. During both placebo and β1-237 adrenergic receptor blockade both LADVmean and LADVmax increased from baseline during 238 exposure to all end-tidal gas manipulations. No differences in LADVmean or LADVmax were 239 observed between poikilocapnic, isocapnic or hypercapnic hypoxic conditions. β1-adrenergicall end-tidal gas manipulations. The final mixed effect linear model for LADVmean included 242 subject as a random effect (P < 0.001), and PETO2 (P < 0.001) and PETCO2 (P < 0.01) as fixed 243 effects. Both drug (P = 0.71) and RPP (P = 0.08) were non-significant predictors and excluded 244 from the final model. Similarly, when RPP was replaced by MELV, subject was included as a 245 random effect (P < 0.001), and PETO2 (P < 0.002) and PETCO2 (P < 0.01) as fixed effects. Measurements of RPP and MELV were significantly correlated (r = 0.74, P < 0.01) with each 257 other and their response to end-tidal gas manipulation during placebo and β1-adrenergic receptor 258 blockade are presented in figure 2C and D. All end-tidal gas manipulations caused RPP to 259 increase from baseline during placebo and β1-adrenergic receptor blockade. A significant 260 interaction was identified and post-hoc analysis determined that β1-adrenergic receptor blockade 261 attenuated the RPP response during hypercapnic hypoxia (P < 0.01) but not significantly during 262 poikilocapnic (P = 0.11) or isocapnic hypoxia (P = 0.07). All end-tidal gas manipulations caused 263 an increase in MELV from baseline during both placebo and β1-adrenergic receptor blockade.
Hypercapnic hypoxia caused a further increase in MELV compared to poikilocapnic (P < 0.01) 265 and isocapnic hypoxia (P < 0.01). During β1-adrenergic receptor blockade the MELV response 266 was reduced across all end-tidal gas manipulation conditions, but no interaction was present. 267 Figure 3A and B outline both indices of myocardial O2 demand and LADVmean responses to gas 268 manipulations during control and β1-adrenergic receptor blockade. Both figures indicate that 269 during β1-adrenergic receptor blockade the myocardial O2 demand response was attenuated. 270
Discussion 271
To our knowledge, this is the first study in healthy humans to measure the coronary vascular 272 response to combined arterial PO2 and PCO2 manipulations with and without β1-adrenergic 273 receptor blockade. The data show that despite reductions in RPP and MELV due to β1-adrenergic 274 receptor blockade, the coronary blood velocity response was conserved during poikilocapnic and 275 isocapnic hypoxia. This indicates a direct influence of hypoxemia independent of myocardial O2 276 demand. Furthermore, a synergistic effect of PO2 and PCO2 was observed during hypercapnic 277 hypoxia as evidenced by a plateau in the LADVmean-RPP relationship, suggesting a feed-forward 278 epicardial coronary artery dilation that was absent during β1-adrenergic receptor blockade. In 279 contrast to our hypothesis, coronary hypoxemic vasodilation was conserved despite a significant 280 attenuation of myocardial O2 demand following β1-adrenergic receptor blockade. 281
282
Sympathetic feed-forward coronary vasodilation 283
Our results showed a significant increase in RPP during hypercapnic hypoxia without any further 284 increase in LADVmean leading to an observed plateau in the LADVmean-RPP relationship that was 285 not present during β1-adrenergic receptor blockade (see Figure 3A) . We interpret this plateau in 286 the LADVmean-RPP relationship during hypercapnic hypoxia (denoted by dagger in Figure 3A) as 287 a feed-forward β1-adrenergic vasodilation in the epicardial LAD thereby attenuating the recorded 288 rise in velocity despite an increase in total blood flow. The β1-adrenergic receptor blockade with 289 esmolol abolished this feed-forward dilation and attenuated RPP. At all other time points, feed-290 forward β1-adrenergic dilation is absent, RPP and MELV tend to be reduced, yet LADVmean are 291 similar (see Figure 2) . The suggested β1-adrenergic mediated response within the epicardial 292 artery is supported by the distribution of β-adrenergic receptor subtypes along the coronaryvascular tree. Larger conduit vessels (diameter > 100 μm) exhibit a 2-fold greater distribution of 294 β1-adrenergic receptors compared to β2-adrenergic receptors; whereas smaller resistance vessels 295 (diameter < 100 μm) have a greater β2-adrenergic receptor distribution with approximately 85% 296 of receptors being of the β2-adrenergic receptor subtype (3, 12, 14) . Furthermore, both β1-and 297 β2-adrenergic receptors have been shown to contribute to coronary vasodilation in response to β-298 adrenergic receptor agonists in a non-beating heart model (40) and closed-chest canines under 299 cardiac pacing (29). 300
The conserved coronary vascular response to physiological stimuli we observed during 301 β1-adrenergic receptor blockade (Figure 2A In the current data, we observed a synergistic effect of hypoxia and hypercapnia on the human 315 coronary vascular response that was attenuated by β1-adrenergic receptor blockade. Similarfindings were reported previously in canines under cardiac pacing during which the coronary 317 blood flow response to hypoxia was augmented when combined with hypercapnia (9) 318 Specifically, during hypercapnic hypoxia, a significant increase in RPP and MELV did not lead to 319 a complimentary increase in LADVmean. As described above, this finding suggests dilation in the 320 epicardial artery that attenuated the recorded rise in LADV despite increases in blood flow. In 321 contrast, the current results show the LADVmean response to hypoxia was not further attenuated 322 by poikilocapnia (see Figure 2) . In the present study, the reduction in PCO2 during poikilocapnic 323 hypoxia may not have been sufficient to attenuate LADVmean or the change in LADVmean may 324 have been too small to detect. Recent investigations into the isolated effect of CO2 using large 325 changes in PETCO2 (+7-10 mmHg) consistently show increases in coronary blood flow and 326 velocity (6, 44, 48). However, the influences of smaller changes in PETCO2 (+4-5 mmHg) have 327 led to conflicting results with some investigations observing increases in coronary blood flow (4) 328 and velocity (6) and others showing no effect (44, 48). The confounding influence of hyperoxia 329 may be responsible for these discrepant findings (44, 48). 330
The current findings of increased LADV in response to hypoxia corroborate previous 331 investigations and there is general agreement that hypoxemia leads to an increase in coronary 332 blood flow in both animals (5, 21, 35) and humans (4, 6, 17, 31). Evidence that hypoxemia has a 333 direct vascular effect in humans is supported by studies which have found that the coronary 334 blood flow response remained after normalizing for changes in myocardial O2 demand (4, 31). 335
In addition, a study from our laboratory, Boulet et al. (6), found nearly equal contributions of 336 hypoxia and cardiac O2 demand toward the coronary vascular response using multiple regression 337 analysis. The data from the current study are consistent with Boulet et al. (6) and support a 338 direct role for hypoxemia in coronary vascular regulation that is independent from changes inmyocardial O2 demand (see Figure 2) . Specifically, we experimentally manipulated myocardial 340 O2 demand and observed no change in the LADV response to poikilocapnic and isocapnic 341 hypoxia. Our data are consistent with the adenine nucleotide hypothesis suggesting that the 342 coronary vascular response to hypoxemia in health is related to endothelial purinergic receptor 343 activation from the release of ATP and its metabolites from erythrocytes rather than pathological 344 cardiomyocyte hypoxia (14, 15, 36) . 345
346
Methodological considerations 347
The current study utilized noninvasive transthoracic Doppler echocardiography to measure 348 LADV which was used as an index for coronary blood flow. This method of non-invasively 349 Our data show reduced myocardial O2 demand in RPP and MELV measurements due to 360 β1-adrenergic receptor blockade with esmolol (Table 2, and Figure 2) . Esmolol was chosen due 361 to its fast mechanism of action, and quick elimination half-life, allowing a single subject to betested in one laboratory visit (39) thereby minimizing the larger day-to-day variability and 363 associated extraneous factors. Previous investigations comparing esmolol to propranolol, a 364 nonspecific β-adrenergic receptor antagonist, show comparable HR and MAP reducing effects of 365 esmolol at an infusion dose similar to that used in the present study (32). Higher doses of 366 esmolol have previously been used in experimental studies (2, 23), however there is a lack of 367 strong evidence to suggest a higher dose of esmolol would have resulted in a greater reduction in 368 HR and blood pressure in response to hypoxia (45). Interestingly, esmolol did not significantly 369 reduce HR during end-tidal gas manipulations (Table 2) . Although this is in contrast to previous 370 experiments involving exercise interventions (27, 32), it may be the result of a greater 371 parasympathetic to sympathetic balance during hypoxia compared with exercise interventions. 372
The dose of esmolol used currently resulted in a clinically relevant reduction in myocardial O2 373 demand as the RPP we observed with esmolol during hypercapnic hypoxia is similar to that 374 experienced by hypertensive patients undergoing treatment with β-adrenergic receptor 375 antagonists (24). 376
377
Conclusion 378
The current data confirm that LADV correlates with RPP and MELV but also indicate that 379 hypoxemia directly increases coronary blood flow independent from changes in myocardial O2 380 demand, potentially through feedback adenine-nucleotide release from red blood cells in 381 response to low blood oxyhemoglobin saturation. Additionally, we found a synergistic effect of 382 O2 and CO2 on the coronary vasculature that manifested as a feed-forward β1-adrenergic dilation 383 in the epicardial artery that was abolished by β1-adrenergic receptor blockade. These findingsdemonstrate a direct influence of arterial PO2 on coronary vascular regulation that is independent 385 from associated changes in myocardial O2 consumption. 386 
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